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Analysis of imported malaria in travelers may represent a
novel surveillance system for drug-resistant malaria. We ana-
lyzed consecutive falciparum malaria isolates from Canadian
travelers from 1994 to 2000, for polymorphisms in pfcrt, dhfr,
and dhps linked to chloroquine and pyrimethamine/sulfadoxine
resistance. Forty percent of isolates possessed the K76 pfcrt
allele, suggesting that many imported falciparum infections are
still responsive to chloroquine. Travelers who had recently
taken chloroquine had a significantly increased risk of harbor-
ing isolates with pfcrt  resistance alleles (odds ratio = 4.47;
p=0.03). The presence of two or more mutations in dhfr or dhps
was found in 64.8% (95% confidence interval [CI] 54.6 to 73.9)
and in 30.4% (95% CI 21.7 to 40.3) of isolates, respectively,
and increased significantly over the course of the study. These
molecular markers indicate that pyrimethamine/sulfadoxine
resistance is increasing and is now too high to rely on this drug
as a routine therapeutic agent to treat malaria in travelers. 
rug-resistant malaria is increasing, and novel strategies to
monitor for resistance are needed. Over 50 million per-
sons from the industrialized world visit malaria-endemic coun-
tries annually, and record numbers of imported malaria cases
are being reported in North America and Europe (1). The first
well-documented cases of chloroquine-resistant and sulfadox-
ine-pyrimethamine (SP)–resistant Plasmodium falciparum
malaria were identified in tourists visiting East Africa in the
late 1970s and early 1980s, which suggests that travelers may
represent an important sentinel population to monitor for drug-
resistant malaria (2,3). Although assessing travelers for
malaria treatment and prophylaxis failures may be an effective
strategy for detecting emerging drug resistance, traditional
methods of detecting resistance, including in vivo treatment
trials and in vitro drug susceptibility testing, are time- and
labor-intensive and are not well suited to large-scale surveil-
lance of travelers (4). 
Molecular methods that detect genetic markers of drug
resistance in parasites are potentially powerful tools to detect
and track drug-resistant malaria. The molecular basis of resis-
tance to antifolate drugs such as SP has been well character-
ized. High-level pyrimethamine resistance results from the
accumulation of mutations in the dhfr gene, principally at
codons 108, 59, and 51 (5,6). Similarly, point mutations in
dhps have been associated with decreased susceptibility to sul-
fadoxine in vitro (7). Chloroquine resistance has been linked
to mutations in two genes, pfmdr1 and pfcrt, that encode the
digestive vacuole transmembrane proteins Pgh1 and PfCRT,
respectively (8–13). Transfection studies with pfmdr1 suggest
that mutations in Pgh1 may modulate the chloroquine resis-
tance phenotype in vitro; however, in vivo studies have shown
an inconsistent association between mutations in Pgh1 and
chloroquine resistance (9–12). More recently, a series of point
mutations in pfcrt have been associated with chloroquine resis-
tance (13). One mutation at position 76 (K76T) was present in
all in vitro resistant parasites and has been proposed as a
molecular marker for surveillance of chloroquine-resistant fal-
ciparum malaria, particularly in nonimmune populations such
as travelers (10,13). 
The objectives of this study were to establish a molecular
surveillance system for imported malaria, to determine and
track the prevalence of putative molecular markers of drug
resistance, and to examine risk factors for infection with iso-
lates bearing resistance markers. 
Materials and Methods
From January 1, 1994, to June 30, 2000, patients seen at
the Toronto General Hospital or the Hospital for Sick Children
in Toronto, Canada, with microscopically confirmed falci-
parum malaria were enrolled. Patient interviews were con-
ducted or medical charts were reviewed for potential risk
factors for infection and drug resistance by using a standard-
ized data extraction form. This study was approved by the
Institutional Review Boards of the Toronto General Hospital
and the Hospital for Sick Children. 
Falciparum isolates were characterized by polymerase
chain reaction-restriction fragment length polymorphism anal-
ysis and sequencing for allelic variants of pfcrt and pfmdr1,
dhfr, and dhps as described (5–17). Proportions were com-
pared by using the chi-square test or Fisher exact test, as
appropriate. The chi-square test for trend was used as required
for variables that involved ordered categories. For the purpose
of this analysis, we considered mixed isolates (e.g., isolates
containing parasites with mutant and wild-type alleles) to be
mutant ones and compared them against those possessing only
wild-type alleles. 
Results
During the study period, 105 consecutive cases of imported
falciparum malaria were recorded (69 males, 36 females; age
range 1–70 years [mean 30.5]). The geographic regions in which
these persons acquired their infections are shown in Table 1.  *Toronto General Hospital, University of Toronto, Canada
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The prevalence of mutations in chloroquine-resistance
markers (pfmdr1 and pfcrt) was significantly higher in isolates
acquired in East Africa compared with West Africa (Table 1).
Patients who acquired malaria infection in East Africa had a
4.5-fold higher risk of being infected by an isolate possessing
the K76T mutation in pfcrt (odds ratio [OR] 4.53 [95% confi-
dence interval (CI) 1.26 to 16.02]; p=0.03) than those visiting
West Africa. The N86Y mutation in pfmdr1 was also found
more often in isolates acquired in East Africa than in those
acquired in West Africa (OR 3.56 [95% CI 1.16 to 10.80];
p=0.03). A linear trend for increasing prevalence of N86Y
mutant isolates was evident during the study period (OR per
year =1.21; p=0.07) (Table 2). We also examined the associa-
tion between past chloroquine exposure and the prevalence of
chloroquine-resistance markers. Nineteen (18.1%) patients
had used chloroquine for prophylaxis (n=13) or treatment
(n=6) while abroad. These persons had a significantly
increased risk of being infected by an isolate harboring the
K76T mutation when compared with other travelers (OR=4.47
[95% CI 1.13 to 25.45]; p=0.03).
We grouped the parasite dhfr and dhps genotypes into four
categories on the basis of the cumulative number of mutations
that have been linked to escalating SP resistance (Table 1).
More mutations in dhps were found in isolates from travelers
returning from West Africa versus East Africa (p=0.001,
Fisher exact test). We found that the proportion of isolates with
at least two mutations increased during the study period in
both dhfr (OR for a 1-unit increase in year = 1.28; p=0.02, chi-
square test for trend) and dhps (OR=1.29; p=0.03) (Table 2).
Discussion
In this study, we demonstrate “proof-of-principle” that a
molecular surveillance strategy based on imported malaria in
travelers can be used to detect and track drug-resistant malaria.
Monitoring travelers for imported drug-resistant malaria is a
surveillance strategy that offers several potential advantages.
Recommendations regarding treatment regimens and chemo-
prophylaxis for travelers should ideally be made on the basis
of the efficacy of these drugs in nonimmune travelers rather
than on partially immune persons residing in malaria-endemic
Table 1. Prevalence of molecular markers of drug resistance by region of malaria acquisition
Area of endemicity n (%) Total
Genotypes West Africaa East  Africab Central  Africac Southern  Africad Othere n (%; 95%CI)f
pfmdr1 
N86 (wild) 40 (59.7) 5 (29.4) 1 (20.0) 1 (33.3) 6 (75.0) 53 (53.0; 42.8 to 63.1)
86Y (mutant) 27 (40.3) 12 (70.6) 4 (80.0) 2 (66.7) 2 (25.0) 47 (47.0; 36.9 to 57.2)
pfcrt
K76 (wild) 32 (49.2) 3 (17.6) 3 (60.0) 0 1 (11.1) 39 (39.8; 30.0 to 50.2)
76T (mutant) 33 (50.8) 14 (82.4) 2 (40.0) 2 (100)  8 (88.9) 59 (60.2; 49.8 to 70.0)
dhfrg
Wild-type 17 (25.0) 3 (17.6) 3 (60.0) 1 (33.3) 2 (22.2) 26 (25.5; 17.4 to 35.1)
Single mutants 6 (8.8) 0 0 0 3 (33.3)  9 (8.8; 4.1 to 16.1)
Double mutants 25 (36.8) 8 (47.1) 1 (20.0) 2 (66.7) 3 (33.3) 39 (38.2; 28.8 to 48.4)
Triple mutants 20 (29.4) 6 (35.3) 1 (20.0) 0 1 (11.1) 28 (27.5; 19.1 to 37.2)
dhpsh
Wild-type 3 (4.4) 7 (41.2) 0 2 (66.7) 8 (88.9) 20 (19.6; 12.4 to 28.6)
Single mutants 40 (58.8) 5 (29.4) 5 (100) 1 (33.3) 0 51 (50.0; 40.0 to 60.1)
Double mutants 21 (30.9) 5 (29.4) 0 0 0 26 (25.5; 17.4 to 35.1)
Triple mutants 4 (5.9) 0 0 0 1 (11.1) 5 (4.9; 1.6 to 11.1)
No. of infected patients 71 (67.6) 17 (16.2) 5 (4.8) 3 (2.9) 9 (8.6) 105
aTwo patients had visited more than one country: Ghana (45 patients), Nigeria (21), The Gambia (2 patients), Sierra Leone (3 patients), Burkina Faso (1 patient), Mali (1 patient), and 
Guinea (1 patient).
bThree patients had visited more than one country: Kenya (9 patients), Uganda (6 patients), Tanzania (3 patients), Rwanda (1 patient), and Burundi (1 patient). 
cCentral African Republic (2 patients), Congo (2 patients), and Cameroon (1 patient)
dAngola (2 patients) and Madagascar (1 patient). 
eIndia (5 patients), Malaysia (1 patient), Bali/New Guinea (1 patient), Brazil (1 patient), and Haiti (1 patient).
f CI, confidence interval.
gdhfr: Wild-type: parasites with A16 / C50 / N51 / C59 / S108 / I164 (n = 26). Single mutants: isolates with the S108N alone (n=9). Double mutants: parasites with mutations at codons 
N51I and S108N (n=11), C59R and S108N (n=27), or A16V and S108T (n=1). Triple mutants: parasites with the genotypes of N51I / C59R / S108N (n=27) or C50R / N51I / S108N 
(n=1). Of note, the falciparum isolate with the A16V/S108T mutations was acquired in 1996 by a 12-year-old in Ghana. Those mutations in dhfr were not accompanied by the mutant 
codon I164L, previously associated with pyrimethamine and cycloguanil resistance (17).
hdhps: Wild-type parasites: parasites with S436 / A437 / K540 / A581 / A613 (n=20). Single mutants: isolates with the S436A (n=19) or A437G (n=32) mutation alone. Double 
mutants: parasites with mutations at codons S436A and A437G (n=18), A437G and K540E (n=6), or S436F and A613S (n=2). Triple mutants: parasites with S436A / A437G / A613S 
(n = 3), S436A / A437G / A581G (n=1), or A437G / K540E / A581G (n=1). Note: Some isolates could not be amplified at all loci and account for occasional missing values.Emerging Infectious Diseases  •  Vol. 9, No. 1, January 2003 35
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areas. However, to date there has been little information on the
rates of drug resistance in cases of imported malaria. Using
travelers as a sentinel system provides a mechanism to study
large numbers of persons returning from diverse malaria-
endemic areas. In contrast, traditional studies have often been
based on relatively small numbers of persons residing in geo-
graphically restricted areas. Travelers are generally nonim-
mune, facilitating the interpretation of treatment and
prophylaxis studies since outcome measures are not con-
founded by reinfections and by the varying degrees of immu-
nity present in residents of malaria-endemic areas. Similarly,
correlating the molecular mechanisms of drug resistance to
treatment outcome in travelers may be more straightforward
since these confounding variables can largely be excluded.
Knowledge of the resistance genotypes of malaria parasites
obtained from returning travelers can provide credible and
complementary data for evidence-based recommendations for
both chemoprophylaxis and therapy of malaria in travelers.
The high correlation between mutations in DHFR  and
DHPS and in vitro resistance to pyrimethamine and sulfadox-
ine, further supported by site-directed mutagenesis and trans-
fection experiments, suggests that the epidemiology of
antifolate resistance in P. falciparum can be monitored by
molecular techniques (5–7, 14–17). Furthermore, evidence
exists for an association between a stepwise increase in the
number of mutations in DHFR and DHPS and a corresponding
increase in the level of clinical resistance to SP. In recent in
vivo studies in partially immune persons in Cameroon and
Kenya, multiple mutations in DHFR (e.g., triple mutation at
codons 108, 59, and 51) were associated with early treatment
failure, suggesting that these could be useful markers for pre-
dicting the in vivo efficacy of SP (18–20).
Using molecular markers of antifolate resistance, our study
provides important data on the appropriateness of drugs such
as SP that are currently recommended in North America and
Europe for treatment or self-treatment of malaria in travelers.
We observed that 75%, 66%, and 28% of consecutive
imported isolates had at least one, two, and three mutations in
DHFR, respectively. In DHPS,  corresponding figures were
80%, 30%, and 5%. Furthermore, we found a linear trend for
increasing prevalence mutations in dhfr and dhps during this
study.  These results suggest that antifolate resistance in
imported falciparum malaria is now common and escalating
over time. These observations question the rationale of contin-
ued recommendation of SP as either standby therapy or combi-
nation therapy with quinine for the treatment of P. falciparum
malaria in travelers. However, some caution is needed in
extrapolating our data to predict the in vivo efficacy of SP.
Additional prospective in vivo studies, especially in the non-
immune host, are required to definitively link antifolate
molecular markers with in vivo resistance (18–20). 
We have also collected data on the occurrence of mutations
associated with chloroquine resistance in consecutive
imported falciparum isolates. The overall prevalence of the
N86Y mutation in pfmdr1 and K76T mutation in pfcrt was
47.0% and 60.2%, respectively. Recent in vivo studies have
assessed the association between pfcrt mutations and chloro-
quine response and determined that the K76 allele correctly
predicted successful outcome (9–11). A rapid assay to detect
pfcrt K76T in travelers’ malaria may be useful, since the pres-
ence of the K76 allele would indicate the probable effective-
ness of treatment with chloroquine alone. On the basis of these
findings, we anticipate that at least 40% of our patients would
have responded to chloroquine. However, in the absence of a
rapid test, current recommendations from the World Health
Organization and the Centers for Disease Control and Preven-
tion must be applied, and P. falciparum infections acquired in
areas of known chloroquine resistance should not be treated
with chloroquine.
Chloroquine and SP resistance has been selected by drug
pressure (5,6,10,21). In Mali, the K76T mutation in pfcrt was
observed in persons with persistent or recurrent infection after
Table 2. Proportions of falciparum isolates with chloroquine- or sulfadoxine-pyrimethamine-associated resistance markers by year of acquisition
Proportions of mutant isolates Proportions of isolates with at least 2 mutant codons
Year pfmdr1 (N86Y)b pfcrt (K76T) dhfrc dhpsd
1994 42.9% 9/21 71.4%  15/21 45.5% 10/22 14.3%  3/21
1995 25.0% 2/8 55.6% 5/9 62.5% 5/8 33.3%  3/9
1996 31.6% 6/19 50.0% 9/18 52.4% 11/21 25.0%  5/20
1997 52.9% 9/17 66.7% 10/15 88.2  % 15/17 35.3%  6/17
1998 64.3% 9/14 50.0% 7/14 85.7% 12/14 21.4%  3/14
1999 50.0% 7/14 64.3% 9/14 78.6% 11/14 57.1%  8/14
 2000e 71.4% 5/7 57.1% 4/7 50.0% 3/6 42.9%  3/7
Total 47.0% 47/100 60.2% 59/98 65.7% 67/102 30.4% 31/102
(95% CI) (36.9 to 57.2) (49.8 to 70.0) (54.6 to 73.9) (21.7 to 40.3)
aOR, odds ratio; CI, confidence interval.
bOR for a 1-unit increase in year = 1.21 (95% CI 0.99 to 1.49); p=0.07, chi-square test for trend.
cOR for a 1-unit increase in year = 1.28 (95% CI 1.0 to 1.59); p=0.02, chi-square test for trend.
dOR for a 1-unit increase in year = 1.29 (95% CI 1.03 to 1.61); p=0.03, chi-square test for trend.
eData for year 2000 are from January 1 to June 30. RESEARCH
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chloroquine therapy, indicating selection for this mutation.
Our study extends these observations to travelers; those who
had taken chloroquine for prophylaxis or treatment had a 4.5-
fold higher risk of being infected with an isolate carrying the
K76T mutation. Although the number of isolates studied was
relatively small, our results also indicate that the prevalence of
genotypes associated with chloroquine resistance was signifi-
cantly higher in isolates acquired in East Africa than in those
acquired in West Africa. This observation is consistent with
currently reported epidemiologic patterns (22). The distribu-
tion of chloroquine- and SP-resistant parasites and their degree
of resistance are far from uniform, and regular assessment of
the therapeutic efficacy of chloroquine and SP, such as
obtained with World Health Organization in vivo studies, is
required. Studies such as ours, using travelers as sentinels, can
contribute in a novel and complementary way to the continu-
ous monitoring and tracking of geographic drug-resistance
patterns. A network of digitally linked sites in the developed
world that are performing these analyses in cases of imported
malaria could provide global and timely monitoring.
In summary, our study demonstrates that a molecular sur-
veillance strategy based on imported malaria in travelers can
be used to detect and track patterns of drug-resistant malaria.
Given the high prevalence of observed mutations in dhfr and
dhps, our data provide evidence that raises questions about the
rationale of continued use of SP to treat falciparum malaria in
returned travelers. Our data also indicate that a considerable
proportion of imported falciparum infections are still respon-
sive to chloroquine. 
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